{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:15:06Z","timestamp":1783646106797,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04347-3","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:35:48Z","timestamp":1779150948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Shiho","family":"Goda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Uda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Shiotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kukida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Tanimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Imasato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Date","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoki","family":"Morito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noeru","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Osugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iwasaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsaku","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"4347_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2024.3669","volume":"331","author":"TM Maher","year":"2024","unstructured":"Maher TM. Interstitial lung disease: a review. JAMA. 2024;331:1655\u201365.","journal-title":"JAMA"},{"key":"4347_CR2","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18-47.","journal-title":"Am J Respir Crit Care Med"},{"key":"4347_CR3","doi-asserted-by":"publisher","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","volume":"55","author":"KK Brown","year":"2020","unstructured":"Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020;55:2000085.","journal-title":"Eur Respir J"},{"key":"4347_CR4","first-page":"89","volume":"10","author":"M Inomata","year":"2015","unstructured":"Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid. 2015;10:89\u201398.","journal-title":"Core Evid"},{"key":"4347_CR5","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"4347_CR6","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327.","journal-title":"N Engl J Med"},{"key":"4347_CR7","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00228-024-03720-7","volume":"80","author":"M Kou","year":"2024","unstructured":"Kou M, Jiao Y, Li Z, Wei B, Li Y, Cai Y, et al. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2024;80:1445\u201360.","journal-title":"Eur J Clin Pharmacol"},{"key":"4347_CR8","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1378\/chest.06-2784","volume":"131","author":"M Alakhras","year":"2007","unstructured":"Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest. 2007;131:1448\u201353.","journal-title":"Chest"},{"key":"4347_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12931-020-01528-4","volume":"21","author":"S Jouneau","year":"2020","unstructured":"Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Valenzuela C, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020;21:312.","journal-title":"Respir Res"},{"key":"4347_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12931-023-02371-z","volume":"24","author":"M Kreuter","year":"2023","unstructured":"Kreuter M, Bendstrup E, Jouneau S, Maher TM, Inoue Y, Miede C, et al. Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial. Respir Res. 2023;24:71.","journal-title":"Respir Res"},{"key":"4347_CR11","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.chest.2021.11.008","volume":"161","author":"A Comes","year":"2022","unstructured":"Comes A, Wong AW, Fisher JH, Morisset J, Johannson KA, Farrand E, et al. Association of BMI and change in weight with mortality in patients with fibrotic interstitial lung disease. Chest. 2022;161:1320\u20139.","journal-title":"Chest"},{"key":"4347_CR12","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.21037\/jtd.2016.12.49","volume":"8","author":"T Kishaba","year":"2016","unstructured":"Kishaba T, Nagano H, Nei Y, Yamashiro S. Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis. 2016;8:3596\u2013604.","journal-title":"J Thorac Dis"},{"key":"4347_CR13","doi-asserted-by":"publisher","first-page":"17842","DOI":"10.1038\/s41598-024-68754-4","volume":"14","author":"E Chung","year":"2024","unstructured":"Chung E, Woo A, Yong SH, Park Y, Lee SH, Kim SY, et al. Malnutrition is associated with mortality in Sj\u00f6gren\u2019s syndrome-associated interstitial lung disease. Sci Rep. 2024;14:17842.","journal-title":"Sci Rep"},{"key":"4347_CR14","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.clnu.2022.05.001","volume":"41","author":"S Jouneau","year":"2022","unstructured":"Jouneau S, Rousseau C, Lederlin M, Lescoat A, Kerjouan M, Chauvin P, et al. Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. Clin Nutr. 2022;41:1335\u201342.","journal-title":"Clin Nutr"},{"key":"4347_CR15","doi-asserted-by":"publisher","first-page":"S1332","DOI":"10.21037\/jtd.2018.02.66","volume":"10","author":"J Gea","year":"2018","unstructured":"Gea J, Sancho-Mu\u00f1oz A, Chalela R. Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations. J Thorac Dis. 2018;10:S1332\u201354.","journal-title":"J Thorac Dis"},{"key":"4347_CR16","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1038\/s41598-025-34071-7","volume":"16","author":"S Goda","year":"2025","unstructured":"Goda S, Yamada T, Goto Y, Uda S, Nakao A, Shiotsu S, et al. Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan. Sci Rep. 2025;16:3947.","journal-title":"Sci Rep"},{"key":"4347_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/resp.14609","volume":"29","author":"CJW Stock","year":"2024","unstructured":"Stock CJW, Bray WG, Kouranos V, Jacob J, Kokosi M, George PM, et al. Serum C-reactive protein is associated with earlier mortality across different interstitial lung diseases. Respirology. 2024;29:228\u201334.","journal-title":"Respirology"},{"key":"4347_CR18","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.62347\/JZTW5621","volume":"17","author":"D Tan","year":"2025","unstructured":"Tan D, Shang Y, Wang J, Sheng N. Predictive role of inflammatory markers in characterizing the progression of interstitial lung disease: a retrospective analysis. Am J Transl Res. 2025;17:3485\u201395.","journal-title":"Am J Transl Res"},{"key":"4347_CR19","doi-asserted-by":"publisher","first-page":"e0255365","DOI":"10.1371\/journal.pone.0255365","volume":"16","author":"JH Lee","year":"2021","unstructured":"Lee JH, Jang JH, Park JH, Jang HJ, Park CS, Lee S, et al. The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases. PLoS ONE. 2021;16:e0255365.","journal-title":"PLoS ONE"},{"key":"4347_CR20","doi-asserted-by":"publisher","first-page":"e22636","DOI":"10.1002\/jcla.22636","volume":"33","author":"T Kaya","year":"2019","unstructured":"Kaya T, A\u00e7\u0131kg\u00f6z SB, Y\u0131ld\u0131r\u0131m M, Nalbant A, Alta\u015f AE, Cinemre H. Association between neutrophil-to-lymphocyte ratio and nutritional status in geriatric patients. J Clin Lab Anal. 2019;33:e22636.","journal-title":"J Clin Lab Anal"},{"key":"4347_CR21","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.3390\/ijms23073636","volume":"23","author":"A Buonacera","year":"2022","unstructured":"Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci. 2022;23:3636.","journal-title":"Int J Mol Sci"},{"key":"4347_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12890-025-03677-y","volume":"25","author":"L Fang","year":"2025","unstructured":"Fang L, Zhu J, Fu D. Predictive value of neutrophil-lymphocyte ratio for all-cause mortality in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med. 2025;25:206.","journal-title":"BMC Pulm Med"},{"key":"4347_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12094-016-1593-y","volume":"19","author":"V Bar-Ad","year":"2017","unstructured":"Bar-Ad V, Palmer J, Li L, Lai Y, Lu B, Myers RE, et al. Neutrophil to lymphocyte ratio associated with prognosis of lung cancer. Clin Transl Oncol. 2017;19:711\u20137.","journal-title":"Clin Transl Oncol"},{"key":"4347_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3892\/mco.2017.1342","volume":"7","author":"Y Yu","year":"2017","unstructured":"Yu Y, Qian L, Cui J. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patients. Mol Clin Oncol. 2017;7:498\u2013506.","journal-title":"Mol Clin Oncol"},{"key":"4347_CR25","doi-asserted-by":"publisher","first-page":"101758","DOI":"10.1016\/j.eclinm.2022.101758","volume":"55","author":"TA Mikolasch","year":"2022","unstructured":"Mikolasch TA, George PM, Sahota J, Nancarrow T, Barratt SL, Woodhead FA, et al. Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosis. EClinicalMedicine. 2022;55:101758.","journal-title":"EClinicalMedicine"},{"key":"4347_CR26","doi-asserted-by":"publisher","first-page":"882217","DOI":"10.3389\/fimmu.2022.882217","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Cai J, Zhang M, Yan X. Prognostic role of NLR, PLR and MHR in patients with idiopathic pulmonary fibrosis. Front Immunol. 2022;13:882217.","journal-title":"Front Immunol"},{"key":"4347_CR27","doi-asserted-by":"publisher","first-page":"e001202","DOI":"10.1136\/bmjresp-2022-001202","volume":"9","author":"A Achaiah","year":"2022","unstructured":"Achaiah A, Rathnapala A, Pereira A, Bothwell H, Dwivedi K, Barker R, et al. Neutrophil lymphocyte ratio as an indicator for disease progression in idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2022;9:e001202.","journal-title":"BMJ Open Respir Res"},{"key":"4347_CR28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00408-020-00386-7","volume":"198","author":"A Zinellu","year":"2020","unstructured":"Zinellu A, Paliogiannis P, Sotgiu E, Mellino S, Mangoni AA, Zinellu E, et al. Blood cell count derived inflammation indexes in patients with idiopathic pulmonary fibrosis. Lung. 2020;198:821\u20137.","journal-title":"Lung"},{"key":"4347_CR29","doi-asserted-by":"publisher","first-page":"e0286956","DOI":"10.1371\/journal.pone.0286956","volume":"18","author":"F Dong","year":"2023","unstructured":"Dong F, Zheng L, An W, Xue T, Zhong X. A meta-analysis of the clinical significance of neutrophil-to-lymphocyte ratios in interstitial lung disease. PLoS ONE. 2023;18:e0286956.","journal-title":"PLoS ONE"},{"key":"4347_CR30","doi-asserted-by":"crossref","unstructured":"Keret S, Yaari S, Shouval A, Sawaed A, Nemesh N, Kaly L, et al. Neutrophil-to-lymphocyte ratio as a biomarker for disease onset and mortality risk in systemic sclerosis: a real-world national cohort study. Rheumatology (Oxford). 2026;65:keaf664.","DOI":"10.1093\/rheumatology\/keag041"},{"key":"4347_CR31","doi-asserted-by":"publisher","first-page":"2004538","DOI":"10.1183\/13993003.04538-2020","volume":"59","author":"KR Flaherty","year":"2022","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2022;59:2004538.","journal-title":"Eur Respir J"},{"key":"4347_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"key":"4347_CR33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.resinv.2022.07.004","volume":"60","author":"S Homma","year":"2022","unstructured":"Homma S, Suda T, Hongo Y, Yoshida M, Hiroi S, Iwasaki K, et al. Incidence and changes in treatment of acute exacerbation of idiopathic pulmonary fibrosis in Japan: a claims-based retrospective study. Respir Investig. 2022;60:798\u2013805.","journal-title":"Respir Investig"},{"key":"4347_CR34","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"4347_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.7326\/0003-4819-84-3-304","volume":"84","author":"AS Fauci","year":"1976","unstructured":"Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84:304\u201315.","journal-title":"Ann Intern Med"},{"key":"4347_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2174\/138945011794751555","volume":"12","author":"AS Saffar","year":"2011","unstructured":"Saffar AS, Ashdown H, Gounni AS. The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr Drug Targets. 2011;12:556\u201362.","journal-title":"Curr Drug Targets"},{"key":"4347_CR37","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1038\/s41598-021-85328-w","volume":"11","author":"A Lauko","year":"2021","unstructured":"Lauko A, Thapa B, Sharma M, Muhsen B, Barnett A, Rauf Y, et al. Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases. Sci Rep. 2021;11:7490.","journal-title":"Sci Rep"},{"key":"4347_CR38","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1084\/jem.20110551","volume":"208","author":"TA Wynn","year":"2011","unstructured":"Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208:1339\u201350.","journal-title":"J Exp Med"},{"key":"4347_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","volume":"80","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis. 2021;80:143\u201350.","journal-title":"Ann Rheum Dis"},{"key":"4347_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1165\/rcmb.2016-0121TR","volume":"55","author":"S Kolahian","year":"2016","unstructured":"Kolahian S, Fernandez IE, Eickelberg O, Hartl D. Immune mechanisms in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2016;55:309\u201322.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"4347_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fmed.2018.00043","volume":"5","author":"O Desai","year":"2018","unstructured":"Desai O, Winkler J, Minasyan M, Herzog EL. The role of immune and inflammatory cells in idiopathic pulmonary fibrosis. Front Med (Lausanne). 2018;5:43.","journal-title":"Front Med (Lausanne)"},{"key":"4347_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12931-018-0730-2","volume":"19","author":"G Sgalla","year":"2018","unstructured":"Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018;19:32.","journal-title":"Respir Res"},{"key":"4347_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1189\/jlb.0707504","volume":"83","author":"IG Luzina","year":"2008","unstructured":"Luzina IG, Todd NW, Iacono AT, Atamas SP. Roles of T lymphocytes in pulmonary fibrosis. J Leukoc Biol. 2008;83:237\u201344.","journal-title":"J Leukoc Biol"},{"key":"4347_CR44","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.4049\/jimmunol.1004081","volume":"187","author":"S Mi","year":"2011","unstructured":"Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG, et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol. 2011;187:3003\u201314.","journal-title":"J Immunol"},{"key":"4347_CR45","doi-asserted-by":"publisher","first-page":"e143226","DOI":"10.1172\/JCI143226","volume":"131","author":"K Shenderov","year":"2021","unstructured":"Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest. 2021;131:e143226.","journal-title":"J Clin Invest"},{"key":"4347_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.rmed.2018.12.015","volume":"147","author":"P Heukels","year":"2019","unstructured":"Heukels P, Moor CC, von der Th\u00fcsen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79\u201391.","journal-title":"Respir Med"},{"key":"4347_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/biom15010122","volume":"15","author":"S Harada","year":"2025","unstructured":"Harada S, Kato M, Nakagome K, Sasano H, Tanabe Y, Takeshige T, et al. Evaluating the diagnostic value of lymphocyte subsets in bronchoalveolar lavage fluid and peripheral blood across various diffuse interstitial lung disease subtypes. Biomolecules. 2025;15:122.","journal-title":"Biomolecules"},{"key":"4347_CR48","doi-asserted-by":"publisher","first-page":"1408880","DOI":"10.3389\/fimmu.2024.1408880","volume":"15","author":"A Hirano","year":"2024","unstructured":"Hirano A, Sakashita A, Fujii W, Ba\u00dfler K, Tsuji T, Kadoya M, et al. Immunological characteristics of bronchoalveolar lavage fluid and blood across connective tissue disease-associated interstitial lung diseases. Front Immunol. 2024;15:1408880.","journal-title":"Front Immunol"},{"key":"4347_CR49","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/0192-0561(87)90070-1","volume":"9","author":"SC Thompson","year":"1987","unstructured":"Thompson SC, Bowen KM, Burton RC. The effect of immunosuppressive agents on lymphocyte subsets in rat peripheral blood. Int J Immunopharmacol. 1987;9:747\u201359.","journal-title":"Int J Immunopharmacol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04347-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:03:08Z","timestamp":1783645388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04347-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4347"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04347-3","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of the Kyoto Prefectural University of Medicine (No. ERB-C-3278). The need for informed consent was waived due to the retrospective nature of the study, and an opt-out opinion was made available on the institution website, as approved by the ethics committee of the Kyoto Prefectural University of Medicine. Approval was also obtained from the ethics committees of all participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"306"}}